Histone deacetylase inhibitor chidamide regulates the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL
Explore this paper's citation graph
Summary
The findings indicate that chidamide might be used alone or in combination with other chemotherapy regimens for patients with B-all and thus provide a new approach to the treatment of B-ALL.
- Type
- article
- Published
- 2021-02-10
- Cited by
- 11
- References
- 43
- OpenAlex
- https://openalex.org/W3126958487
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:231858949
Keywords
Wnt signaling pathway, Histone deacetylase, Histone deacetylase inhibitor, Acetylation, Cancer research
References
- MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells
- How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
- Acute Lymphoblastic Leukemia in Children.
- Epigenetic aberrations during oncogenesis
- Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia.
- Wnt signaling in the intestinal epithelium: from endoderm to cancer.
- SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.
- Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia.
- A decade of exploring the cancer epigenome — biological and translational implications
- Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
- Dkk3, downregulated in cervical cancer, functions as a negative regulator of β‐catenin
- MYC recruits the TIP60 histone acetyltransferase complex to chromatin
- Wnt/Frizzled signaling in hepatocellular carcinoma.
- Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia
- Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
- Myc proteins as therapeutic targets
- Leukemogenesis: More Than Mutant Genes
- The fundamental role of epigenetics in hematopoietic malignancies.
- MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma
- Clinical updates in adult acute lymphoblastic leukemia.
Cited by
- The interaction of canonical Wnt/β-catenin signaling with protein lysine acetylation
- Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
- Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study
- Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
- Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells
- Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL
- DKK3 as a novel biomarker for risk stratification in pediatric acute lymphoblastic leukemia
- Discovery of Tertiary Benzenesulfonanilide Chemotypes as HDAC Inhibitors via Multistrategy In Silico and Biological Evaluation for Colon Cancer Therapy.
- Additional file 2 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 3 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 1 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 10 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 3 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 2 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 1 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Additional file 10 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax
- Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies
Related papers
- Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
- Regulatory Roles of Histone Deacetylases 1 and 2 in Pb-induced Neurotoxicity
- Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma
- Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase
- Update of histone deacetylase inhibitors
- Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
- Isoform-selective histone deacetylase inhibitors.
- Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition.
- The Effect of Histone Deacetylase Inhibitor on the Expression Level of Glucococrticoid Receptor in Rat Forebrain under Hypoxia
- HDAC, a key to pRb tumour suppression?